Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Is Soaring Today

By Zhiyuan Sun – Aug 5, 2021 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceuticals company is showing surprising resilience in the face of competition.

What happened? 

Shares of Amarin (AMRN -4.27%) are up 9% to $4.84 apiece as of 2:30 p.m. EDT. The company released spectacular second-quarter earnings. Revenue went up 14% year over year to $154.5 million. Simultaneously its net income grew to $6.2 million compared to a loss of $16.1 million. Amarin lost a patent litigation challenge to its flagship cardiovascular disease management/fish oil drug Vascepa last year. However, data from Symphony Health Solutions show that Vascepa still commands 89% market share eight months after generic entrants launched. 

An elderly person taking a fish oil pill.

Image source: Getty Images.

So what 

Branded drug prices and prescription volume can decline by as much as 90% within 12 months of generics hitting the market. Investors had much of that bad news priced in for Amarin and were surprised to see otherwise. What's more, keep in mind that the patent loss only applies to U.S. jurisdictions. The company plans to launch Vascepa in the U.K. and Germany this year. Its European patents do not expire until 2039. 

Now what 

Amarin stock is pretty undervalued at the moment. The company has a cash balance of $521.3 million and no debt, giving it an enterprise value (EV) of just $1.23 billion -- leaving it an EV-to-sales multiple of just two. Going forward, I think Vascepa's European commercialization will be enough to offset generic competition in the U.S. market. The healthcare stock looks like an ideal choice for investors to buy on the dip. It already lost 32% of its value since the year started and a rebound is long overdue. 

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
Amarin
AMRN
$1.12 (-4.27%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.